A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Published in:

PLoS ONE, 2021, v. 16, n. 9, p. 1, doi. 10.1371/journal.pone.0248222

By:

• Demarchi, Martin;
• Coliat, Pierre;
• Barthelemy, Philippe;
• Schott, Roland;
• BenAbdelghani, Meher;
• Kim, Michael;
• Hii, Jocelyn Chung Shii;
• Feyaerts, Peggy;
• Ang, Felicia Rui Xia;
• Derde, Marie Paule;
• Deforce, Filip;
• Petit, Thierry;
• Schwabe, Chris;
• Wynne, Chris;
• Park, Lisa Soyeon;
• Pivot, Xavier

Publication type:

Article